Exam 3 Flashcards
Types of acute leukemia
Lymphocytic (lymphoblastic) and Myelogenous (non-lymphocytic)
Types of chronic leukemia
Lymphocytic and Myelogenous
Hereditary risks for acute leukemia
Down’s syndrome, Fanconi’s anemia, Bloom’s syndrome, and primary immunodeficiency
Environmental risks for acute leukemia
Radiation, Chemicals, Chemotherapy
features of acute leukemia
Anemia, Leukocytosis, Thrombocytopenia, increased LDH, increased lysozyme, increased uric acid, increased B12/folate binding proteins, increased LFT’s and renal dysfunction
AML with multilineage dysplasia
Dysplasia in >50% of cells of at least 2 lineages, chromosomal abnormalities similar to those found in MDS
AML therapy-related, alkylating agents, radiation
Usually occur 5-6 years post-therapy, risk related to cumulative dose and patient age, Chromosomal abnormalities, some similar to MDS
AML therapy-related, topoisomerase II inhibitors and anthracyclines
Occur 1-10 years post-therapy, chromosomal abnormalities, some of 11q23
Acute leukemia subtyping
Bone and/or marrow aspirate morphology, cytochemistry, indirect immunofluorescence, flow cytometry immunophenotyping, clinical history, cytogenetics
M0-AML with minimal differentation
,3% blasts MPO/SBB positive, blasts positive for myeloid antigens, blasts negative for lymphoid antigens
M1-AML without maturation
> 3% blasts MPO/SBB positive, <10% promyelocytes plus mature granulocytes
M2-AML with maturation
> 3% blasts MPO/SBB positive, >10% promyelocytes plus mature granulocytes
M4-AML
> 20% blasts granulocytic, >20% blasts monocytic
M5-Acute monoblastic (a) and monocytic (b) leukemia
> 80% leukemic cells monocytic, M5a-majority of monocytic cells are monoblasts, M5b-majority of monocytic cells are promyelocytes
M6-Acute erythroid leukemia
> 50% of marrow cells erythroid, >20% nonerythroid cells myeloblasts, Variant: pure erythroid leukemia with >80% marrow cells immature erythroid cells with no significant myeloblastic component